SG11201808106YA - Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation - Google Patents
Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulationInfo
- Publication number
- SG11201808106YA SG11201808106YA SG11201808106YA SG11201808106YA SG11201808106YA SG 11201808106Y A SG11201808106Y A SG 11201808106YA SG 11201808106Y A SG11201808106Y A SG 11201808106YA SG 11201808106Y A SG11201808106Y A SG 11201808106YA SG 11201808106Y A SG11201808106Y A SG 11201808106YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- lateral sclerosis
- amyotrophic lateral
- masitinib
- pct
- Prior art date
Links
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 title abstract 5
- 239000002139 L01XE22 - Masitinib Substances 0.000 title abstract 3
- WJEOLQLKVOPQFV-UHFFFAOYSA-N masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 title abstract 3
- 229960004655 masitinib Drugs 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 241000928106 Alain Species 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 210000003630 histaminocyte Anatomy 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000000977 initiatory effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16162490 | 2016-03-25 | ||
| PCT/EP2017/057134 WO2017162884A1 (en) | 2016-03-25 | 2017-03-24 | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808106YA true SG11201808106YA (en) | 2018-10-30 |
Family
ID=55637258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808106YA SG11201808106YA (en) | 2016-03-25 | 2017-03-24 | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10092564B2 (enExample) |
| EP (1) | EP3240538B1 (enExample) |
| JP (2) | JP7250312B2 (enExample) |
| KR (1) | KR102293847B1 (enExample) |
| CN (1) | CN108883108B (enExample) |
| AU (1) | AU2017236177B2 (enExample) |
| BR (1) | BR112018069515A2 (enExample) |
| CA (1) | CA3018635C (enExample) |
| DK (1) | DK3240538T3 (enExample) |
| EA (1) | EA038531B1 (enExample) |
| ES (1) | ES2899929T3 (enExample) |
| HU (1) | HUE057398T2 (enExample) |
| IL (1) | IL261856B (enExample) |
| MX (1) | MX390495B (enExample) |
| NZ (1) | NZ745778A (enExample) |
| PL (1) | PL3240538T3 (enExample) |
| PT (1) | PT3240538T (enExample) |
| SG (1) | SG11201808106YA (enExample) |
| SI (1) | SI3240538T1 (enExample) |
| WO (1) | WO2017162884A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| CN104869993B (zh) | 2012-10-25 | 2019-01-15 | 通用医疗公司 | 治疗阿尔茨海默病及相关疾病的组合疗法 |
| US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
| AU2014340182B2 (en) | 2013-10-22 | 2019-05-23 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| US20190240194A1 (en) * | 2016-08-31 | 2019-08-08 | The General Hospital Corporation | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases |
| MX379222B (es) | 2016-11-25 | 2025-03-10 | Genuv Inc | Composición para promover la diferenciación y protección de células madre neurales y método para inducir la regeneración neural usando las mismas. |
| CA3057040A1 (en) * | 2017-03-28 | 2018-10-04 | Novartis Ag | New methods for the treatment of multiple sclerosis |
| BR112019025346A2 (pt) * | 2017-05-30 | 2020-06-30 | Deciphera Pharmaceuticals, Inc. | uso de 1-[4-bromo-5-[1-etil-7-(metilamino)-2-oxo-1,2-dihidro-1,6-naftiridin-3-il]-2-fluorofenil]-3-fenilureia e análogos para o tratamento de cânceres associados a anormalidades genéticas no receptor alfa do fator de crescimento derivado de plaquetas |
| US11692029B2 (en) | 2018-03-05 | 2023-07-04 | The Schepens Eye Research Institute, Inc. | Therapy for glaucoma and optic neuropathy by targeting colony stimulating factors |
| KR20210071943A (ko) | 2018-07-02 | 2021-06-16 | 더 제너럴 하스피탈 코포레이션 | 크로몰린 소듐 및 α-락토스의 분말화된 제형 |
| US12383528B2 (en) | 2018-12-10 | 2025-08-12 | The General Hospital Corporation | Cromolyn esters and uses thereof |
| CN112618717A (zh) * | 2019-09-24 | 2021-04-09 | 北京大学深圳研究生院 | Btk抑制剂用于治疗肌萎缩侧索硬化症的用途 |
| FI4084779T3 (fi) * | 2019-12-30 | 2024-12-16 | Deciphera Pharmaceuticals Llc | 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia |
| WO2021207060A1 (en) | 2020-04-06 | 2021-10-14 | The General Hospital Corporation | Methods of treatment of coronavirus-induced inflammation conditions |
| US12612391B2 (en) | 2020-12-28 | 2026-04-28 | The General Hospital Corporation | Cromolyn derivatives and uses thereof |
| US20250129067A1 (en) * | 2021-11-08 | 2025-04-24 | Progentos Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
| WO2025113494A1 (zh) * | 2023-11-27 | 2025-06-05 | 浙江径科医药有限公司 | 多环类化合物及其应用 |
| WO2026015576A1 (en) * | 2024-07-09 | 2026-01-15 | PhenoNet, Inc. | Methods and systems for treatment of neurodegenerative disease and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW225528B (enExample) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| US8450302B2 (en) | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| MXPA05001277A (es) | 2002-08-02 | 2005-10-06 | Ab Science | 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit. |
| HRP20110709T1 (hr) | 2007-02-13 | 2011-11-30 | Ab Science | Postupak sinteze spojeva 2-aminotioazola kao inhibitora kinaza |
| TW201204360A (en) | 2010-04-20 | 2012-02-01 | Ab Science | Treatment of multiple sclerosis with MASITINIB |
| CN109316480A (zh) | 2011-07-13 | 2019-02-12 | 赛特凯恩蒂克公司 | 组合als疗法 |
| AU2013326463B2 (en) * | 2012-10-04 | 2018-01-18 | Ab Science | Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors |
| EP2970317A4 (en) * | 2013-03-15 | 2016-11-02 | Dana Farber Cancer Inst Inc | PYRIMIDODIAZEPINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF DISEASES |
| US20160263110A1 (en) * | 2013-11-04 | 2016-09-15 | Ab Science | Use of masitinib for treatment of amyotrophic lateral sclerosis |
-
2017
- 2017-03-24 EA EA201800499A patent/EA038531B1/ru unknown
- 2017-03-24 MX MX2018011349A patent/MX390495B/es unknown
- 2017-03-24 DK DK17712175.3T patent/DK3240538T3/da active
- 2017-03-24 EP EP17712175.3A patent/EP3240538B1/en active Active
- 2017-03-24 US US15/545,800 patent/US10092564B2/en active Active
- 2017-03-24 KR KR1020187026871A patent/KR102293847B1/ko active Active
- 2017-03-24 WO PCT/EP2017/057134 patent/WO2017162884A1/en not_active Ceased
- 2017-03-24 HU HUE17712175A patent/HUE057398T2/hu unknown
- 2017-03-24 NZ NZ745778A patent/NZ745778A/en not_active IP Right Cessation
- 2017-03-24 PT PT177121753T patent/PT3240538T/pt unknown
- 2017-03-24 SI SI201730997T patent/SI3240538T1/sl unknown
- 2017-03-24 ES ES17712175T patent/ES2899929T3/es active Active
- 2017-03-24 AU AU2017236177A patent/AU2017236177B2/en active Active
- 2017-03-24 CN CN201780019760.9A patent/CN108883108B/zh active Active
- 2017-03-24 PL PL17712175T patent/PL3240538T3/pl unknown
- 2017-03-24 SG SG11201808106YA patent/SG11201808106YA/en unknown
- 2017-03-24 CA CA3018635A patent/CA3018635C/en active Active
- 2017-03-24 JP JP2018549902A patent/JP7250312B2/ja active Active
- 2017-03-24 BR BR112018069515A patent/BR112018069515A2/pt not_active Application Discontinuation
-
2018
- 2018-09-20 IL IL261856A patent/IL261856B/en unknown
-
2021
- 2021-12-16 JP JP2021204244A patent/JP2022037132A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3240538A1 (en) | 2017-11-08 |
| NZ745778A (en) | 2022-07-01 |
| WO2017162884A1 (en) | 2017-09-28 |
| US10092564B2 (en) | 2018-10-09 |
| CN108883108B (zh) | 2021-08-06 |
| CA3018635A1 (en) | 2017-09-28 |
| JP2019515884A (ja) | 2019-06-13 |
| IL261856B (en) | 2022-04-01 |
| MX2018011349A (es) | 2019-02-07 |
| CA3018635C (en) | 2023-09-26 |
| AU2017236177A1 (en) | 2018-09-20 |
| MX390495B (es) | 2025-03-20 |
| EA038531B1 (ru) | 2021-09-10 |
| PL3240538T3 (pl) | 2022-01-31 |
| DK3240538T3 (da) | 2021-12-06 |
| US20180117037A1 (en) | 2018-05-03 |
| IL261856A (en) | 2018-10-31 |
| EA201800499A1 (ru) | 2019-03-29 |
| CN108883108A (zh) | 2018-11-23 |
| KR20180125966A (ko) | 2018-11-26 |
| PT3240538T (pt) | 2021-12-07 |
| EP3240538B1 (en) | 2021-09-29 |
| ES2899929T3 (es) | 2022-03-15 |
| BR112018069515A2 (pt) | 2019-04-16 |
| SI3240538T1 (sl) | 2022-02-28 |
| JP7250312B2 (ja) | 2023-04-03 |
| HUE057398T2 (hu) | 2022-05-28 |
| KR102293847B1 (ko) | 2021-08-26 |
| AU2017236177B2 (en) | 2022-03-31 |
| JP2022037132A (ja) | 2022-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201907673YA (en) | Pharmaceutical compositions for combination therapy | |
| SG11201901494UA (en) | Acid-alpha glucosidase variants and uses thereof | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201900021PA (en) | Methods and compositions for the treatment of cancer | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201804885TA (en) | Monomaleimide-functionalized platinum compounds for cancer therapy | |
| SG11201808540SA (en) | Methods of treatment for cholestatic and fibrotic diseases | |
| SG11201903312VA (en) | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine | |
| SG11201901762WA (en) | Methods and composition for the prediction of the activity of enzastaurin | |
| SG11201809541UA (en) | Immune checkpoint inhibitors and cytotoxic t cells for the treatment of cancer | |
| SG11201806424TA (en) | Therapeutic compounds | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201901249YA (en) | Aza-indazole compounds for use in tendon and/or ligament injuries |